We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients (MRSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00941356
Recruitment Status : Suspended (Unable to recruit patients to continue on with the study.)
First Posted : July 17, 2009
Last Update Posted : January 15, 2016
Centre Hospitalier Pierre-Le Gardeur
Information provided by (Responsible Party):
Bio-K Plus International Inc.

January 15, 2009
July 17, 2009
January 15, 2016
January 2010
July 2016   (Final data collection date for primary outcome measure)
Frequency of subjects with MRSA decolonization [ Time Frame: 21 days ]
nasal decolonisation after use of the study product [ Time Frame: 21 days ]
Complete list of historical versions of study NCT00941356 on ClinicalTrials.gov Archive Site
To evaluate the secondary effects (incidence rate of non-serious ans serious adverse events)associated to the administration of the study product [ Time Frame: 21 days ]
To evaluate the secondary effects associated to the administration of the study product [ Time Frame: 21 days ]
Not Provided
Not Provided
Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients
A Single Center, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients

Trial Objectives:

Primary objective:

  • To evaluate the efficacy of Bio-K+CL1285® in patients with Methicillin-Resistant S. aureus (MRSA) nasal colonization by comparing the MRSA decolonization following either Bio-K+CL1285® or placebo treatment.

Secondary objective:

  • To evaluate the safety profile of Bio-K+CL1285®.

Study Design:

Double-blind, randomized (1:1 randomization), placebo-controlled, single center Canadian study.

Patients will be randomly assigned to one of the two study products. A randomization schedule will be generated by the sponsor for each participating centre. This schedule will link patient identification numbers to one of the two study products allocated at random. The schedule will be prepared on a 1:1 randomization ratio.

The study products will be labelled with the patient identification number. Patients have to be randomized in the order in which they qualify from the screening phase for inclusion in the study.

Patients withdrawn from the study retain their patient number if already given. New patients must always be allotted a new identification number (PIN).

Study Duration:

The duration of patient participation in the study will be between 22 and 23 days. The overall duration of the study is expected to be approximately 10 months; with subject recruitment proposed to start in March 2009, the last follow-up visit is expected in May 2010. The actual overall study duration or subject recruitment period may vary.

Number of Sites (inside and outside of Canada):

One center in the province of Quebec will be involved in the study.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
MRSA Colonization
  • Dietary Supplement: Bio-K+ CL1285
    2 capsules per day before breakfast
    Other Name: Bio-K+ CL1285(R) Extra Strength
  • Dietary Supplement: Placebo
    2 capsules per day before breakfast
  • Experimental: 1
    Bio-K+ CL1285 contains 50 billion of live bacteria
    Intervention: Dietary Supplement: Bio-K+ CL1285
  • Placebo Comparator: 2
    placebo devoid of bacteria
    Intervention: Dietary Supplement: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
July 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients having ≥18 years of age
  • Women of child bearing capacity who are not pregnant at the moment of screening (Pregnancy test done on-site) and agree to use an acceptable form of birth control for the duration of the study (e.g. condom, oral contraceptives, etc.) are allowed to participate.
  • Patients must have nasal MRSA colonization confirmed with MRSA positive culture as assessed during the screening visit without any clinical signs or symptoms of infection.
  • Laboratory test results within the normal ranges.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients treated for nasal MRSA decolonization in the last 6 months;
  • Current infection with MRSA;
  • Ongoing or active infection;
  • Daily probiotic/ fermented milk or Yogurt use;
  • Known to have shown a previous reaction, including anaphylaxis, to any substance in composition of the study agent (capsules);
  • Ongoing or recent use of antibiotics in the 30 days prior to the study agent administration;
  • Pregnancy, breastfeeding;
  • Regular use of nasal agents;
  • Uncontrolled intercurrent illness, including situations that would limit compliance with study requirements;
  • Patients with open wounds
  • Immunosuppressive therapy or any health condition causing inmunosuppression (Including Haematological malignancies, AIDS);
  • Ostomized patients, parenteral nutrition users;
  • Patients with current vascular access (catheter) or planned to have installed a vascular access (catheter) or any prosthesis during the study period.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Bio-K Plus International Inc.
Bio-K Plus International Inc.
Centre Hospitalier Pierre-Le Gardeur
Principal Investigator: Dr Pierre-Jean PM Maziade, MD Pierre Le Gardeur Hospital
Bio-K Plus International Inc.
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP